Avenue Biosciences
Latest round
- Seed
Last raised
- Jan 2026
Total raised
- $8.2M
Investors
- 6
About Avenue Biosciences
Founded in 2023 in California, US, Avenue Biosciences Oy engaged in protein engineering. In January 2026, Avenue Biosciences, Inc. The company was co-founded by Tero-Pekka Alastalo (CEO), Katja Rosti, and Juho Kellosalo. Avenue Biosciences offers advanced protein engineering solution powered by machine learning, focusing on enhancing the production yield and quality of biologics. Their core offerings include a proprietary platform that simultaneously analyzes thousands of naturally occurring and genetically engineered signal peptides, significantly improving protein expression, particularly for difficult-to-express proteins. This technology is applicable across various sectors, including biotechnology tools, therapeutic development, and vaccine discovery, catering to clients involved in mRNA therapies, synthetic proteins, and biosimilars. Avenue Biosciences aims to serve a global market, targeting regions with biopharmaceutical industries, including North America, Europe, and parts of Asia. Avenue Biosciences generates revenue through partnerships and collaborations with other companies in the biotechnology and pharmaceutical sectors. The company’s revenue structure consists of service agreements where clients engage Avenue Biosciences to employ its protein engineering platform for specific projects, potentially leading to long-term collaborations. This includes fee-for-service agreements or milestone payments based on successful outcomes, such as enhanced protein yields or the successful development of new therapies. The firm also pursues revenue through licensing agreements for its proprietary technologies, allowing clients to utilize Avenue’s innovations in their own research and development efforts. Specific pricing plans are determined based on the scope and scale of services rendered, aligning with the industry standards for advanced biopharmaceutical development.
Who invested in Avenue Biosciences
6 investors across 2 rounds
See all investors in Avenue Biosciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Avenue Biosciences
Who invested in Avenue Biosciences?
Avenue Biosciences has 6 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Avenue Biosciences raised?
Avenue Biosciences has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Avenue Biosciences last raise money?
Avenue Biosciences's most recent round on record is a Seed, in Jan 2026.
What does Avenue Biosciences do?
Founded in 2023 in California, US, Avenue Biosciences Oy engaged in protein engineering.
Where is Avenue Biosciences headquartered?
Avenue Biosciences is headquartered in Palo Alto, US.
Which VCs invest in companies like Avenue Biosciences?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Avenue Biosciences's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Avenue Biosciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.